NTE 122

Drug Profile

NTE 122

Latest Information Update: 05 Dec 2003

Price : $50

At a glance

  • Originator Nissin Food Products
  • Class Antihyperlipidaemics; Cyclohexanes
  • Mechanism of Action Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atherosclerosis; Hyperlipidaemia

Most Recent Events

  • 05 Dec 2003 No development reported - Preclinical for Hyperlipidaemia in Japan (unspecified route)
  • 05 Dec 2003 No development reported - Preclinical for Atherosclerosis in Japan (unspecified route)
  • 01 Jan 2001 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top